AFT appoints Anita Baldauf as a director

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com





Market and media release 4th November 2020

AFT appoints Anita Baldauf as a director
AFT Pharmaceuticals (NZX; AFT, ASX; AFP) has today appointed Anita Baldauf as a
non-executive director.
The appointment fills the vacancy left by Nathan Hukill who, as president of the
company’s former major shareholder CRG, resigned in June 2020 following CRG’s sale
of its shareholding in AFT.
Chair David Flacks says: “We are delighted to welcome Anita to the Board. She brings
an outstanding mix of experience in international business development, finance,
compliance, personnel development and governance through her 22-year career
with Nestlé.
“More recently she has been advising New Zealand start-ups and new ventures as
they navigate through the challenges of growth and changing market environments.
“All of this is directly relevant to AFT as we grow and consolidate our presence in
Australasia and build our presence internationally with our Maxigesic® pain relief and
other medications,” Mr Flacks said.
Ms Baldauf says she is looking forward to supporting the board, Managing Director Dr
Atkinson and the AFT team to continue its strong growth trajectory.

“Since coming to New Zealand 18 months ago, I have observed AFT and consider it
a shining example of Kiwi ingenuity and entrepreneurship,” Ms Baldauf says.

“Over more than two decades Hartley and the team have carved out a significant
share of pharmaceutical markets in Australasia and a growing share globally.

“They have achieved this with smart ideas that are backed up by robust clinical
research. I am looking forward to working with the team on the next phase of this
exciting journey.”

Ms Baldauf, who is also a fellow of the Edmund Hillary Fellowship, an organisation
aimed at developing solutions to global problems, will stand for re -election to the
board at next year’s Annual Shareholders Meeting.

For and on behalf of AFT Pharmaceuticals Limited by Malcolm Tubby, Chief Financial
Officer.

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com




For more information:
Investors Media
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232

About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical company that develops, markets and
distributes a broad portfolio of pharmaceutical products across a wide range of
therapeutic categories which are distributed across all major pharmaceutical
distribution channels: over-the-counter (OTC), prescription and hospital. Our product
portfolio comprises both proprietary and in-licensed products, and includes patented,
branded and generic drugs. Our business model is to develop and in-license products
for sale by our own dedicated sales teams in our home markets of Australia and New
Zealand and in certain Southeast Asian markets, and to out-license our products to
local licensees and distributors to over 125 countries around the world. For more
information about the company, visit our website www.aftpharm.com
.